“…For proinflammatory stimuli, lipopolysaccharide (LPS, 100 ng/ml, R&D Systems, USA) and IFN-γ (3 ng/ml, R&D Systems, USA) were added to the fresh medium. To inhibit UPR, MPC-myotubes were treated with 4-phenyl butyric acid (4-PBA) (10 mM, UPR inhibitor, Selleck, Shanghai, China), 4μ8c (50 mM, IRE1α pathway inhibitor, Selleck), or GSK2606414 (1 mM, PERK pathway inhibitor, which can directly bind to PERK and inhibits its activity, Selleck) for about 4 h [ 15 , 29 ]. For activating UPR, MPC-myotubes were treated with tunicamycin (TM, 1 mg/ml, Santa Cruz California, USA) or thapsigargin (Tg, 0.2 mmol/l, Santa Cruz) for about 4 h [ 15 , 30 , 31 ].…”